Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343. 10-year follow up of a phase 2 clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results